Stephanie Gaillard

Johns Hopkins University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (5)

Lainie Martin

University of Pennsylvania Perelman School of Medicine

UNITED STATES

View details

Andrea Wahner Hendrickson

Associate Professor of Oncology and Pharmacology

Mayo Clinic

UNITED STATES

View details

Susana Banerjee

Reader in Women's Cancers (Systemic Therapy and Clinical Trials)

Institute of Cancer Research

UNITED KINGDOM

View details

Rakesha Regina Davis Young Lopez Brooks

Head of State

UNITED STATES

View details

Kwong-Kwok Wong

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephanie Gaillard

Research Interests

Explore related searches

Contact this professor

Articles (10)

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Association of glutaminase expression with immune-suppressive tumor microenvironment, clinicopathologic features, and clinical outcomes in endometrial cancer

Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced stage dedifferentiated endometrial carcinoma

Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series

Uterine MEIS1::NCOA2 Fusion Sarcoma With Lung Metastasis: A Case Report and Review of the Literature

Low-grade serous ovarian cancer: expert consensus report on the state of the science

Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

NCCN GUIDELINES® INSIGHTS Cervical Cancer, Version 1.2024

Collaborators (5)

Lainie Martin

Andrea Wahner Hendrickson

Susana Banerjee

Rakesha Regina Davis Young Lopez Brooks

Kwong-Kwok Wong

Make your next move.